Article
Oncology
Taylor W. Butler, Nadeen T. Ali, Mateusz J. Spalek, Sara Scott, Nikolaos Tsoukalas
Summary: This review examines the available evidence for risk assessment and primary thromboprophylaxis for oncology patients hospitalized for acute medical illness. The results show that risk assessments for thrombosis are primarily based on studies conducted in the general population and there is a lack of specific risk assessment for oncology patients. Evidence for thromboprophylaxis in oncology patients is conflicting and mainly comes from sub-group analysis of larger studies in the general population. The strength of recommendations from international guidelines is limited due to the lack of sufficient evidence. Future research should focus on improving risk assessment and understanding the appropriate treatment for this patient population.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Hematology
Nils Picker, Agnes Y. Lee, Alexander T. Cohen, Anthony Maraveyas, Jan Beyer-Westendorf, Lorenzo G. Mantovani, Khaled Abdelgawwad, Samuel Fatoba, Inga-Marion Thate-Waschke, Miriam Bach, Thomas Wilke
Summary: This study revealed that in cancer-associated VTE treatment decision making, patients predominantly prioritize route of administration, with a strong preference for oral administration and treatment without dietary restrictions. Patients also showed preferences for shorter distance to treating physician and once-daily dosing.
THROMBOSIS AND HAEMOSTASIS
(2021)
Article
Oncology
Marc Carrier, Normand Blais, Mark Crowther, Petr Kavan, Gregoire Le Gal, Otto Moodley, Sudeep Shivakumar, Deepa Suryanarayan, Vicky Tagalakis, Cynthia Wu, Agnes Y. Y. Lee
Summary: Patients with CAT are at high risk for complications, and anticoagulant therapy should be tailored based on factors such as bleeding risk, cancer type, and drug interactions. The treatment algorithm should be adapted as the patient's cancer status and management evolve.
Article
Medicine, General & Internal
Paula Jimenez-Fonseca, Enrique Gallardo, Fernando Arranz Arija, Jesus Manuel Blanco, Ana Callejo, Diego Cacho Lavin, Marinha Costa Rivas, Joaquin Mosquera, Alberto Rodrigo, Raul Sanchez Morillas, Maria Vares Gonzalez, Andres Munoz, Alberto Carmona-Bayonas
Summary: This review provides practical recommendations for complex, clinically relevant situations regarding the prevention and management of cancer-associated venous thromboembolism (CAT). The authors emphasize the importance of individualized decisions and the lack of strong evidence-based recommendations in this field.
EUROPEAN JOURNAL OF INTERNAL MEDICINE
(2022)
Review
Oncology
Marta Masini, Matteo Toma, Paolo Spallarossa, Italo Porto, Pietro Ameri
Summary: RCTs have demonstrated that rivaroxaban, edoxaban, and apixaban are equally effective as LMWH in treating CAT, but increase the risk of major gastrointestinal bleeding. Apixaban and rivaroxaban can also prevent CAT in high-risk chemotherapy patients, but may lead to higher bleeding likelihood. Limited data is available for using DOAC in individuals with intracranial tumors or thrombocytopenia, and drug interactions with anticancer agents may affect DOAC effectiveness-safety profile. Current guidelines recommend DOAC as the first-line anticoagulants for CAT, but caution should be exercised in specific patient subgroups.
CURRENT ONCOLOGY REPORTS
(2023)
Article
Green & Sustainable Science & Technology
Shuto Mikami, Yutaka Ito, Hernan Gabriel Oyola Gonzales
Summary: The study analyzed the preferences of Peruvian university mining students for labor conditions and found that optimizing labor conditions at mining sites can be achieved by adjusting them based on the characteristics of potential workers. This will create a more efficient working environment for companies and workers.
Article
Hematology
Nadia Abelhad, Wei Qiao, Naveen Garg, Cristhiam M. Rojas-Hernandez
Summary: This study retrospectively reviewed the treatment of cerebral venous thrombosis in 45 cancer patients, finding recanalization in nearly 60% of cases, a recurrence or propagation rate of 15.6% at 12 months, and major bleeding complications in 15 patients. The findings suggest a narrow therapeutic index of anticoagulation in cancer patients with CVT, highlighting the importance of careful monitoring for anticoagulation effect and bleeding complications. Further larger and controlled studies are needed to validate these observations.
THROMBOSIS JOURNAL
(2021)
Article
Oncology
Courtney P. Williams, Kathleen D. Gallagher, Katie Deehr, Monica S. Aswani, Andres Azuero, Casey L. Daniel, Eric W. Ford, Stacey A. Ingram, Alan J. Balch, Gabrielle B. Rocque
Summary: The study found that breast cancer patients prioritize affordability or maintaining functional independence when making treatment decisions. Therefore, evaluating patient preferences during treatment decision-making could optimize their treatment experiences.
Article
Environmental Studies
Marie Hubatova, James McGinlay, David J. J. Parsons, Joe Morris, Anil R. R. Graves
Summary: This study applies Q methodology to group people according to their preferences for Cultural Ecosystem Services (CES). Four groups were identified: Inspired by nature, Conserving nature, Countryside mix, and Outdoor pursuits. These groups emphasize the importance of visiting the countryside, understanding nature, and having sensory experiences to enhance the benefits from nature.
Article
Medicine, General & Internal
Alessandro Squizzato, Silvia Galliazzo, Elena Rancan, Marina Di Pilla, Giorgia Micucci, Gianmarco Podda, Emanuele Valeriani, Leonardo Campiotti, Lorenza Bertu, Walter Ageno, Ettore Porreca, Corrado Lodigiani
Summary: The optimal management of venous thromboembolism (VTE) in cancer patients with thrombocytopenia remains uncertain. The study found that different therapeutic strategies were associated with varying degrees of thrombocytopenia, and individualized anticoagulation strategies should be tailored based on the patient's platelet count, VTE presentation, and the presence of cerebral metastasis.
INTERNAL AND EMERGENCY MEDICINE
(2022)
Article
Hematology
Omri Cohen, Lucia Maria Caiano, Antonella Tufano, Walter Ageno
Summary: Splanchnic vein thrombosis (SVT) is often associated with cancer and myeloproliferative neoplasms (MPNs), presenting with nonspecific clinical symptoms and frequently being incidentally diagnosed during cancer staging or follow-up imaging studies. The occurrence of SVT predicts worse prognosis in patients with liver or pancreatic cancer, suggesting the presence of an underlying malignancy or MPN. Patients with cancer-related SVT have a high risk of VTE extension and recurrence, with long-term anticoagulant treatment recommended in the absence of high bleeding risk.
SEMINARS IN THROMBOSIS AND HEMOSTASIS
(2021)
Article
Virology
Antoni Riera-Mestre, Luis Jara-Palomares, Ramon Lecumberri, Javier Trujillo-Santos, Enric Grau, Angeles Blanco-Molina, Ana Piera Carbonell, Sonia Jimenez, Manuel Frias Vargas, Mari Paz Fuset, Sergi Bellmunt-Montoya, Manuel Monreal, David Jimenez
Summary: The study used DELPHI methodology to answer PICO questions related to anticoagulation in patients with COVID-19 and reached a consensus on seven recommendations, including avoiding pharmacological thromboprophylaxis, LMWH treatment, and routine monitoring of D-Dimer levels.
Review
Medicine, General & Internal
Patrick J. Lindsay, Rachel Rosovsky, Edward A. Bittner, Marvin G. Chang
Summary: COVID-19-associated coagulopathy (CAC) is a recognized hematologic complication in severe COVID-19 patients, where thrombosis can cause multiorgan injury. Guidelines for managing CAC are based on expert consensus and current evidence, but there are still many clinical scenarios with varying expert opinions.
POSTGRADUATE MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Hannah C. Puhr, Ayseguel Ilhan-Mutlu, Matthias Preusser, Peter Quehenberger, Paul A. Kyrle, Sabine Eichinger, Lisbeth Eischer
Summary: Direct oral anticoagulants (DOACs) are safe and effective in cancer patients treated for venous thromboembolism (VTE) or atrial fibrillation (AF) after gastrectomy. However, caution should be exercised when using dabigatran in this patient population due to the risk of recurrent thromboembolic events.
Article
Medicine, Research & Experimental
Paul Johannet, Amelia Sawyers, Nicholas Gulati, Douglas Donnelly, Samuel Kozloff, Yingzhi Qian, Alfredo Floristan, Eva Hernando, Judy Zhong, Iman Osman
Summary: The study found that patients receiving anticoagulation therapy did not experience better treatment outcomes when receiving immune checkpoint inhibitors, and were instead more likely to suffer from major or clinically relevant bleeding complications.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Article
Health Care Sciences & Services
Stephanie Sivell, Hayley Prout, Noreen Hopewell-Kelly, Jessica Baillie, Anthony Byrne, Michelle Edwards, Emily Harrop, Simon Noble, Catherine Sampson, Annmarie Nelson
BMJ SUPPORTIVE & PALLIATIVE CARE
(2019)
Article
Health Care Sciences & Services
Huw Williams, Sir Liam Donaldson, Simon Noble, Peter Hibbert, Rhiannon Watson, Joyce Kenkre, Adrian Edwards, Andrew Carson-Stevens
PALLIATIVE MEDICINE
(2019)
Article
Oncology
Jemima T. Collins, Simon Noble, Helen E. Davies, Daniel Farewell, Jason F. Lester, Diane Parry, Anthony Byrne
EUROPEAN JOURNAL OF CANCER CARE
(2019)
Article
Medicine, General & Internal
Rachael Hunter, Simon Noble, Sarah Lewis, Paul Bennett
Article
Hematology
Clare White, Simon I. R. Noble, Max Watson, Flavia Swan, Victoria L. Allgar, Eoin Napier, Annmarie Nelson, Jayne McAuley, Jennifer Doherty, Bernadette Lee, Miriam J. Johnson
LANCET HAEMATOLOGY
(2019)
Article
Hematology
Aurelien Delluc, Tzu-Fei Wang, Eng-Soo Yap, Cihan Ay, Jordan Schaefer, Marc Carrier, Simon Noble
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2019)
Editorial Material
Health Care Sciences & Services
Josep Porta-Sales, Simon Noble
PALLIATIVE MEDICINE
(2019)
Article
Health Care Sciences & Services
Simon Noble, Sophie Banerjee, Nikki Jane Pease
Summary: Most advanced cancer patients with CAT continue to receive anticoagulation until or within days of death, which increases the risk of bleeding without providing additional benefit in preventing VTE symptoms.
BMJ SUPPORTIVE & PALLIATIVE CARE
(2022)
Review
Health Care Sciences & Services
Tessa Watts, Derek Willis, Simon Noble, Bridget Johnston
CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE
(2019)
Article
Health Care Sciences & Services
Toby Dinnen, Huw Williams, Sarah Yardley, Simon Noble, Adrian Edwards, Peter Hibbert, Joyce Kenkre, Andrew Carson-Stevens
Summary: This study characterizes and explores patient safety incidents arising from Advance Care Planning (ACP) processes in the last phase of life. The study identifies three categories of incidents related to ACP: ACP not completed, ACP completed but not accessible or miscommunicated between professionals, and ACP completed and accessible but not followed. The incidents may result in adverse outcomes such as inappropriate treatment and/or transfer or admission.
BMJ SUPPORTIVE & PALLIATIVE CARE
(2022)
Letter
Hematology
Tracey Woulfe, Kiri Mann, Daryl Pollack, Parinita Swarnkar, Annmarie Nelson, Simon Noble
THROMBOSIS RESEARCH
(2020)
Review
Health Care Sciences & Services
Paul Keeley, Deans Buchanan, Clare Carolan, Lara Pivodic, Simon Tavabie, Simon Noble
BMJ SUPPORTIVE & PALLIATIVE CARE
(2020)
Article
Hematology
Isabelle Mahe, Jean Chidiac, Mickael Pinson, Michele Pinson, Parinita Swarnkar, Annmarie Nelson, Simon Noble
THROMBOSIS RESEARCH
(2020)
Article
Health Care Sciences & Services
Donna Wakefield, Simon Noah Etkind, Lucy Bemand-Qureshi, Anna Sutherland, Jonathan Koffman, Felicity Dewhurst, Simon Noble, Charlotte Chamberlain
Summary: The UK Palliative trainees Research Collaborative (UKPRC) has made significant progress since its inception in 2016 and has the potential to change palliative care practice. Challenges include transitioning from national audits to multisite, patient-facing research, and maintaining continuity in a membership with high turnover.
BMJ SUPPORTIVE & PALLIATIVE CARE
(2022)
Article
Hematology
Thure F. Overvad, Flemming Skjoth, Gregory Piazza, Simon Noble, Anne G. Ording, Torben B. Larsen, Peter B. Nielsen
Summary: The Khorana score can stratify patients with cancer treated with immune checkpoint inhibitors according to the 6-month risk of thromboembolic events. The risk of venous thromboembolism in this population was lower than in randomized thromboprophylaxis trials, which raises questions about the absolute benefit of routine primary thromboprophylaxis for these patients. Higher Khorana risk categories were also associated with a higher 6-month risk of arterial thrombosis and any thromboembolic events.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2022)